Frontotemporal Demans Tedavisi
Özet
Frontotemporal demans (FTD), klinik olarak heterojen sendromların, patolojik ve moleküler olarak farklı ancak örtüşen nörodejeneratif süreçler üzerinden ortaya çıktığı bir hastalık spektrumudur. Klinik sendromlar (bvFTD, PPA varyantları, CBS, PSP-S), frontal ve anterior temporal beyin ağlarının seçici tutulumu ile karakterizedir; ancak altta yatan patoloji çoğu zaman klinik fenotiple bire bir örtüşmez. Bu durum, kliniko-patolojik yakınsama ve fenotipik çeşitlilik kavramlarıyla açıklanır. FTD’nin moleküler temeli, esas olarak üç proteinopatinin birikimine dayanır: tau, TDP-43 ve FUS. Tauopatilerde mikrotübül stabilitesini sağlayan tau proteininin hiperfosforilasyonu ve izoform dengesinin (3R/4R) bozulması, nöronal ve glial agregatlara yol açarak hücresel taşıma ve sinaptik bütünlüğü bozar. TDP-43 ve FUS proteinopatilerinde ise nükleer RNA/DNA bağlayıcı proteinlerin sitoplazmik birikimi, RNA metabolizmasının bozulmasına, toksik protein agregasyonuna ve hücre ölümü süreçlerinin tetiklenmesine neden olur. Genetik mutasyonlar (MAPT, GRN, C9orf72 başta olmak üzere), bu proteinopatileri yönlendirerek özgül patolojik alt tiplerin gelişimine katkıda bulunur. Sonuçta FTD, ağ temelli nörodejenerasyon, protein agregasyonu, glial disfonksiyon ve genetik yatkınlığın etkileşimiyle ilerleyen karmaşık bir mekanistik süreçtir.
Referanslar
Miller BL, Boeve BF. The behavioral neurology of dementia. 2nd edition United Kingdom: Cambridge University Press;2016. https://doi.org/10.1017/ 9781139924771.
Brun A, Liu X, Erikson C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer’s disease and in frontal lobe degeneration. Neuro degeneration 1995;4(2):171–7.
Seeley WW. Mapping neurodegenerative disease onset and progression. Cold SpringHarb Perspect Biol 2017;9(8) (pii:a023622).
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134(Pt 9):2456–77.
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary pro gressive aphasia and its variants. Neurology 2011;76(11):1006–14.
Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51(6):1546–54.
Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr 1987;6(3):193–208.
Kril JJ, Halliday GM. Pathological staging of frontotemporal lobar degeneration. J Mol Neurosci 2011;45(3):379–83.
Sato-Harada R, Okabe S, Umeyama T, et al. Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct Funct 1996;21(5):283–95.
Mandelkow E-M, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. ColdSpringHarb Perspect Med 2012;2(7): a006247.
Munoz DG, Dickson DW, Bergeron C, et al. The neuropathology and biochem istry of frontotemporal dementia. Ann Neurol 2003;54(Suppl 5):S24–8.
Khlistunova I, Biernat J, Wang Y, et al. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006;281(2):1205–14.
Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of cell-to-cell transmission of pathological tau: a review. JAMA Neurol 2019;76(1):101–8.
Arai T, Ikeda K, Akiyama H, et al. Intracellular processing of aggregated tau dif fers between corticobasal degeneration and progressive supranuclear palsy. Neuroreport 2001;12(5):935–8.
Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in pri mary progressive aphasia variants. Ann Neurol 2017;81(3):430–43.
Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behav ioural variant frontotemporal dementia. Brain 2017;140(12):3329–45
Mann DM, South PW, Snowden JS, et al. Dementia of frontal lobe type: neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry 1993; 56(6):605–14.
Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002;58(2): 198–208.
Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999;246(2):6–15.
Bigio EH, Brown DF, White CL 3rd. Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol 1999;58(4):359–64.
Ahmed Z, Bigio EH, Budka H, et al. Globular glial tauopathies (GGT): Consensus recommendations. Acta Neuropathol 2013;126(4):537–44.
Gil MJ, Manzano MS, Cuadrado ML, et al. Argyrophilic Grain pathology in frontotemporal lobar degeneration: demographic, clinical, neuropathological, and genetic features. J Alzheimers Dis 2018;63(3):1109–17.
Vanden Broeck L, Callaerts P, Dermaut B. TDP-43-mediated neurodegeneration: Towards a loss-of-function hypothesis? Trends Mol Med 2014;20(2):66–71.
Mackenzie IRA, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122(1):111–3.
Rohrer JD, Gennatas ED, Trojanowski JQ. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 2010;75(24): 2204–11.
Whitwell JL, Jack CR Jr, Parisi JE, et al. Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci 2011;45(3): 372–8.
Urwin H, Josephs KA, Rohrer JD, et al. FUS pathology defines the majority of tau-and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 2010;120(1):33–41.
Josephs KA, Whitwell JL, Parisi JE, et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol 2010;17(7):969–75.
Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011;24(6):542–9.
Seelaar H, Rohrer JD, Pijnenburg YAL, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011;82(5):476–86.
Pickering-Brown SM, Rollinson S, Du Plessis D, et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: Comparison with patients with MAPT and no known mutations. Brain 2008;131(3):721–31.
Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 2005;65(11):1817–9.
Deleon J, Miller BL. 1st edition. Frontotemporal dementia, vol. 148. Elsevier B.V.; 2018. https://doi.org/10.1016/B978-0-444-64076-5.00027 2.
Khan BK, Woolley JD, Chao S, et al. Schizophrenia or neurodegenerative disease prodrome? outcome of a first psychotic episode in a 35-year-old woman. Psychosomatics 1970;53(3):280–4.
Miyoshi M, Shinotoh H, Wszolek ZK, et al. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study. Parkinsonism Relat Disord 2010;16(6):404–8.
Dopper EGP, Rombouts SARB, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology 2014;83(2):e19–26.
Ghetti B, Oblak AL, Boeve BF, et al. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 2015;41(1):24–46.
Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: A new avenue towards the understanding and treatment of neurodegenerative disease. Brain 2017; 140(12):3081–104.
He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003;81(10):600–12.
Josephs KA, Ahmed Z, Katsuse O, et al. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 2007;66(2):142–51.
Lavergne V, Taft RJ, Alewood PF. Cysteine-rich mini-proteins in human biology. Curr Top Med Chem 2012;12(14):1514–33.
Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442(7105):916–9.
Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a majör cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006;15(20):2988–3001.
Smith KR, Damiano J, Franceschetti S, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 2012;90(6):1102–7.
Kelley BJ, Haidar W, Boeve BF, et al. Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging 2009;30(5):739–51.
Le Ber I, Camuzat A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study. Brain 2008;131(3):732–46.
Snowden JS, Adams J, Harris J, et al. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler FrontotemporalDegener 2015;16(7–8): 497–505.
Caroppo P, Le Ber I, Camuzat A, et al. Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin. JAMA Neurol 2014;71(12):1562–6.
Jacova C, Hsiung G-YR, Tawankanjanachot I, et al. Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology 2013;81(15):1322–31.
Lee SE, Sias AC, Kosik EL, et al. Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. Neuroimage Clin 2019;22:101751.
Pottier C, Zhou X, Perkerson RB, et al. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 2018;17(6):548–58.
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72(2):245–56.
Gomez-Tortosa E, Gallego J, Guerrero-Lopez R, et al. C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration. Neurology 2013;80(4):366–70.
Dobson-Stone C, Hallupp M, Bartley L, et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology 2012; 79(10):995–1001.
Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012;135(3):693–708.
Sha SJ, Takada LT, Rankin KP, et al. Frontotemporal dementia due to C9ORF72 mutations. Neurology 2012;79(10):1002–11.
Lee SE, Khazenzon AM, Trujillo AJ, et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain 2014; 137(Pt 11):3047–60.
Lee SE, Sias AC, Mandelli ML, et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin 2017;14: 286–97.
de Jong D, Jansen RWMM, Pijnenburg YAL, et al. CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 2007; 78(9):936–8.
Skillback T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 2014;83(21):1945–53.
Ljubenkov PA, Staffaroni AM, Rojas JC, et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol 2018;5(10): 1250–63.
Kuiperij HB, Versleijen AAM, Beenes M, et al. Tau rather than TDP-43 proteins are potential cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes: a pilot study. J Alzheimers Dis 2017;55(2):585–95.
Sua´rez-Calvet M, Dols-Icardo O, Llado´ A, et al. Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J Neurol Neurosurg Psychiatry 2014;85(6): 684–91.
Nicholson AM, Finch NCA, Thomas CS, et al. Progranulin protein levels are differently regulated in plasma and CSF. Neurology 2014;82(21):1871–8.
Lehmer C, Oeckl P, Weishaupt JH, et al. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol Med 2017;9(7):859–68.
Paterson RW, Slattery CF, Poole T, et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther 2018;10(1):32.
Miller BL, Chang L, Mena I, et al. Progressive right frontotemporal degeneration: clinical, neuropsychological and SPECT characteristics. Dementia 1993;4(3–4): 204–13.
Rohrer JD, Rosen HJ. Neuroimaging in frontotemporal dementia. Int Rev Psychiatry 2013;25(2):221–9.
Perry RJ, Graham A, Williams G, et al. Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. Dement Geriatr Cogn Disord 2006; 22(4):278–87.
